The American Society of Clinical Oncology has updated its adjuvant therapy guideline for resected non–small-cell lung cancers. Among the recommendations:

• Routine use of adjuvant cisplatin-based chemotherapy is recommended for patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections.
• Adjuvant cisplatin-based chemotherapy is not recommended for routine use in those with stage IB disease.
• Conduct a postoperative multimodality evaluation to assess benefits and risks of adjuvant chemotherapy.
• Do not use adjuvant chemotherapy in patients with stage IA disease.
• Do not use adjuvant radiation therapy in patients with resected stage I or II disease.
• Do not use adjuvant radiation therapy routinely in those with stage IIIA N2 disease.
• Conduct a postoperative multimodality evaluation to assess benefits and risks of adjuvant radiation therapy in patients with N2 disease.

The authors also provide guidance on other factors to consider before recommending adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations.